Latest news with #Dr.Reddys
Business Standard
11-08-2025
- Business
- Business Standard
Dr Reddy's Lab receives EIR from USFDA for Telangana API facility
Dr. Reddy's Laboratories announced that it has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing facility (CTO-5) located in Miryalaguda, Telangana. The USFDA has classified the inspection outcome as "Voluntary Action Indicated" (VAI) and confirmed that the inspection is officially closed. According to an exchange filing dated 24 May 2025, the inspection was conducted between 19 May and 24 May 2025. At the conclusion of the inspection, the USFDA had issued a Form 483 with two observations, which Dr. Reddys stated it would address within the stipulated timeline. Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The companys consolidated net profit rose 1.8% to Rs 1,418.10 crore on 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25. The scrip rose 0.61% to Rs 1,219 on the BSE.
Business Standard
16-06-2025
- Business
- Business Standard
Dr Reddys Laboratories allots Equity shares
Pursuant to ESOPDr Reddys Laboratories has allotted 57,885 equity shares of Re.1/- each of the Company, fully paid up, on June 14, 2025, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddys Employees Stock Options Scheme, 2002 and Dr. Reddys Employees ADR Stock Options Scheme, by Capital Market - Live News
